Table 3.
Summary of adverse events
| Event, n (%) | Total (N = 34) | TQB2450 1200 mg +anlotinib 10 mg (N = 3) | TQB2450 1200 mg +anlotinib 12 mg (N = 31) |
|---|---|---|---|
| SAE | 3 (8.8) | 0 | 3 (9.7) |
| Any TRAE | 34 (100) | 3 (100) | 31 (100) |
| Anlotinib-related | 34 (100) | 3 (100) | 31 (100) |
| TQB2450-related | 34 (100) | 3 (100) | 31 (100) |
| Grade ≥3 TRAE | 17 (50.0) | 2 (66.7) | 15 (48.4) |
| Anlotinib-related | 17 (50.0) | 2 (66.7) | 15 (48.4) |
| TQB2450-related | 15 (44.1) | 2 (66.7) | 13 (41.9) |
TEAE, treatment-emergent adverse event; SAE, serious adverse event; TRAE, treatment-related adverse event. AEs were summarized with descriptive statistics.